Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
KPRX
KPRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
KPRX News
Kiora Pharmaceuticals to Participate in Investor Fireside Chat
6d ago
Yahoo Finance
Kiora Pharmaceuticals Q1 Financial Analysis
May 08 2026
seekingalpha
KIORA PHARMACEUTICALS INC Reports Q1 Loss of $0.58 Per Share in SEC Filing
May 08 2026
moomoo
Kiora Pharmaceuticals Secures $24 Million Financing to Advance Eye Disease Treatments
Apr 07 2026
stocktwits
KIORA PHARMACEUTICALS INC TO OFFER 438,471 COMMON STOCK SHARES THROUGH PRIVATE PLACEMENT - SEC FILING
Apr 07 2026
moomoo
Kiora Pharmaceuticals Reports FY 2025 Financial Results
Mar 25 2026
seekingalpha
Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders
Oct 30 2025
PRnewswire
HC Wainwright & Co. Reiterates Buy on Kiora Pharmaceuticals, Maintains $10 Price Target
Mar 28 2025
Benzinga
HC Wainwright & Co. Reiterates Buy on Kiora Pharmaceuticals, Maintains $10 Price Target
Nov 12 2024
Benzinga
Kiora Pharmaceuticals gets approval to initiate mid-stage trial for eye disorder treatment
Oct 29 2024
SeekingAlpha
Buy Rating on Kiora Pharmaceuticals: Strong Financials and Promising KIO-301 Progress
Aug 10 2024
Business Insider
KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q2 2024
Aug 09 2024
Business Insider
HC Wainwright & Co. Maintains Buy on Kiora Pharmaceuticals, Adjusts Price Target To $10 (1-9 Reverse Stock Split)
Jul 23 2024
Benzinga
Buy Rating on Kiora Pharmaceuticals Amid Strong Financials and Promising Clinical Trials
May 11 2024
Business Insider
KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q1 2024
May 10 2024
Business Insider
Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
Nov 14 2021
globenewswire
Show More News
